AbbVieFRA:4AB +0.68%82 EV-to-FCF is 25.96 as of Jul. 02, 2026, which is 62% above its 10-year median of 16.07. GuruFocus rates FRA:4AB with a GF Score™ of 82/100 and a GF Value™ of €184.72 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 560 Drug Manufacturers companies, AbbVie ranks worse than 54.82% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AbbVie's Enterprise Value is €445,277 Mil.
AbbVie's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €17,152 Mil. Therefore, AbbVie's EV-to-FCF for today is 25.96.
The historical rank and industry rank for AbbVie's EV-to-FCF or its related term are showing as below:
FRA:4AB'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.95 Med: 16.07 Max: 27.17
Current: 25.43
During the past 13 years, the highest EV-to-FCF of AbbVie was 27.17. The lowest was 9.95. And the median was 16.07.
FRA:4AB's EV-to-FCF is ranked worse than 54.82% of 560
companies
in the Drug Manufacturers industry
Industry Median: 20.52
vs FRA:4AB: 25.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-02), AbbVie's stock price is €221.10.
AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.744. Therefore, AbbVie's PE Ratio (TTM) for today is 126.78.
AbbVie (FRA:4AB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AbbVie's share price for today is €221.10.
AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.744.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AbbVie EV-to-FCF Related Terms
AbbVie EV-to-FCF Historical Data
* Premium members only.
The historical data trend for AbbVie's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AbbVie's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AbbVie's EV-to-FCF falls into.
AbbVie's current Enterprise Value is €445,277 Mil.
AbbVie's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €17,152 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (FRA:4AB) has a EV-to-FCF of 25.96 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AbbVie and its competitors. This is 62% above median its historical median of 16.07. Over the past decade, AbbVie's EV-to-FCF has ranged from 9.95 to 27.17. According to the industry distribution chart, AbbVie ranks #307 out of 560 companies in the Drug Manufacturers industry, placing it in the top 54.8%.
Is AbbVie's EV-to-FCF too high?
AbbVie's current EV-to-FCF of 25.96 is 62% above median its 10-year median of 16.07. Over the past 10 years, this metric has ranged from a low of 9.95 to a high of 27.17. The Drug Manufacturers industry median EV-to-FCF is 20.52. AbbVie's value of 25.96 is 26.5% above this industry median. Based on the distribution chart, AbbVie ranks #307 out of 560 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AbbVie has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's EV-to-FCF compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #307 out of 560 companies for EV-to-FCF. This places AbbVie in the lower half of its industry. The industry median EV-to-FCF is 20.52. AbbVie's value of 25.96 is 26.5% above this benchmark. Historically, AbbVie's own EV-to-FCF has ranged from 9.95 to 27.17 over the past decade. While the company's 10-year median is 16.07 vs. the industry median of 20.52, AbbVie has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.52, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current EV-to-FCF of 25.96 is 26.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current EV-to-FCF is 25.96, which is 62% above median its own 10-year median of 16.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (FRA:4AB) is currently considered Modestly Overvalued. The stock's GF Value™ is €184.72, compared to a current price of €221.10 — trading 19.7% above its estimated fair value. The current EV-to-FCF is 25.96, which is 62% above median its 10-year median of 16.07 and 26.5% above the Drug Manufacturers industry median of 20.52. AbbVie's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For AbbVie (FRA:4AB), the current EV-to-FCF is 25.96 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (FRA:4AB) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of €221.10 is trading 19.7% above its estimated GF Value™ of €184.72.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for FRA:4AB:
EV-to-FCF: 25.96 (62% above median its 10-year median of 16.07)
GF Value™: €184.72 vs. price of €221.10 (19.7% above fair value)
Industry Position: 26.5% above the Drug Manufacturers median (#307 of 560)
No single metric tells the full story. See the FRA:4AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
82GF Score
Get the complete analysis for FRA:4AB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4AB has been successfully added to your 
